Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth.

The OX-40 receptor (OX-40R) is a cell surface glycoprotein of the tumor necrosis factor receptor family that is expressed primarily on activated CD4 T cells. Engagement of OX-40R by the OX-40 ligand (OX-40L) is known to costimulate the production of cytokines by activated T lymphocytes and to rescue effector T cells from activation-induced cell death. It was previously reported that in vivo ligation of OX-40R by administration of OX-40L:immunoglobulin fusion protein or OX-40R monoclonal antibody (mAb) resulted in a significant prolongation of survival of tumor-bearing mice in four histologically distinct solid tumors. In this study, we demonstrate that the therapeutic efficacy of OX-40R mAb was influenced by the tumor burden, the intrinsic immunogenicity of the tumor as well as by the histological site of tumor growth. Whereas subdermal and intracranial growth of weakly immunogenic MCA 203 and MCA 205 sarcomas and GL261 glioma were susceptible to the mAb treatment, established pulmonary MCA 205 metastases were refractory to the same regimen of treatment. Furthermore, the mAb administration had no impact on the growth of the poorly immunogenic B16/D5 mela noma. Tumor regression mediated by OX-40R mAb was dependent on the participation of both CD4 and CD8 T cells and as a result of tumor rejection, a long-term tumor-specific immunity was established. Analysis of tumor-infiltrating T cells revealed the presence of a far greater number of OX-40R+ T cells of both CD4 and CD8 phenotypes in the intracranial immunogenic GL261 glioma than that in the poorly immunogenic B16/D5 melanoma. These results suggest that ligation of OX-40R on activated T cells in situ in the tumor may provide a necessary costimulatory signal to augment immune responses leading to tumor regression and immunological memory.

[1]  G. Alvord,et al.  Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity1 , 2000, The Journal of Immunology.

[2]  T. Noda,et al.  Impairment of Antigen-Presenting Cell Function in Mice Lacking Expression of Ox40 Ligand , 2000, The Journal of experimental medicine.

[3]  A. Weinberg,et al.  Danger and OX40 Receptor Signaling Synergize to Enhance Memory T Cell Survival by Inhibiting Peripheral Deletion1 , 2000, The Journal of Immunology.

[4]  J. Shimizu,et al.  Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. , 1999, Journal of immunology.

[5]  T. Ohno,et al.  Induction of effective antitumor immunity in a mouse brain tumor model using B7‐1 (CD80) and intercellular adhesive molecule 1 (ICAM‐1; CD54) transfection and recombinant interleukin 12 , 1999, International journal of cancer.

[6]  T. Fujita,et al.  Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. , 1999, Cancer research.

[7]  P. Dore‐Duffy,et al.  Role of central nervous system microvascular pericytes in activation of antigen‐primed splenic T‐lymphocytes , 1999, Journal of neuroscience research.

[8]  A. Weinberg,et al.  Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. , 1999, Journal of immunology.

[9]  S. McDonald,et al.  Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein. , 1999, Journal of immunology.

[10]  M. Croft,et al.  Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. , 1998, Journal of immunology.

[11]  B. Kwon,et al.  Role of 4-1BB in immune responses. , 1998, Seminars in immunology.

[12]  Y. Tanaka,et al.  OX40 costimulation enhances interleukin-4 (IL-4) expression at priming and promotes the differentiation of naive human CD4(+) T cells into high IL-4-producing effectors. , 1998, Blood.

[13]  B. Fox,et al.  Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile. , 1998, Journal of immunology.

[14]  K. Toellner,et al.  CD4 T Cell Cytokine Differentiation: The B Cell Activation Molecule, OX40 Ligand, Instructs CD4 T Cells to Express Interleukin 4 and Upregulates Expression of the Chemokine Receptor, Blr-1 , 1998, The Journal of experimental medicine.

[15]  H. Kagamu,et al.  Purification of L-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes. , 1998, Journal of immunology.

[16]  E. Shevach,et al.  CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. , 1998, Journal of immunology.

[17]  M. Croft,et al.  Partial activation of naive CD4 T cells and tolerance induction in response to peptide presented by resting B cells. , 1997, Journal of immunology.

[18]  A. Weinberg,et al.  Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers. , 1997, American journal of surgery.

[19]  A. Aruffo,et al.  4-1BB Costimulatory Signals Preferentially Induce CD8+ T Cell Proliferation and Lead to the Amplification In Vivo of Cytotoxic T Cell Responses , 1997, The Journal of experimental medicine.

[20]  A. Weinberg,et al.  Expression of the T-cell activation antigen, OX-40, identifies alloreactive T cells in acute graft-versus-host disease. , 1997, Blood.

[21]  G. Dranoff,et al.  Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells. , 1997, Human gene therapy.

[22]  Lieping Chen,et al.  Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors , 1997, Nature Medicine.

[23]  D. Green,et al.  Unequal Death in T Helper Cell (Th)1 and Th2 Effectors: Th1, but not Th2, Effectors Undergo Rapid Fas/FasL-mediated Apoptosis , 1997, The Journal of experimental medicine.

[24]  G. Plautz,et al.  Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells. , 1996, Cancer research.

[25]  R. Flavell,et al.  The Role of CD40 Ligand in Costimulation and T‐Cell Activation , 1996, Immunological reviews.

[26]  E. Fuchs,et al.  CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. , 1996, Immunity.

[27]  A. Barclay,et al.  OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand , 1996, European journal of immunology.

[28]  A. Vandenbark,et al.  Vβ CDR3 motifs associated with BP recognition are enriched in OX‐40+ spinal cord T cells of lewis rats with EAE , 1996, Journal of neuroscience research.

[29]  J. Bluestone,et al.  CD28/B7 system of T cell costimulation. , 1996, Annual review of immunology.

[30]  D. Bourdette,et al.  Selective depletion of myelin–reactive T cells with the anti–OX–40 antibody ameliorates autoimmune encephalomyelitis , 1996, Nature Medicine.

[31]  A. Weinberg,et al.  OX‐40 antibody enhances for autoantigen specific Vβ8.2+ T cells within the spinal cord of lewis rats with autoimmune encephalomyelitis , 1996, Journal of neuroscience research.

[32]  J. Gribben,et al.  Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. , 1994, Blood.

[33]  J. Johnston,et al.  B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum. , 1994, Cancer research.

[34]  M. Seldin,et al.  Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV‐1‐regulated protein gp34. , 1994, The EMBO journal.

[35]  R. Noelle,et al.  The role of CD40 in the regulation of humoral and cell-mediated immunity. , 1994, Immunology today.

[36]  D. Loh,et al.  Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. , 1994, Immunity.

[37]  T. Miyawaki,et al.  Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. , 1992, Journal of immunology.

[38]  S. Rosenberg,et al.  A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability , 1992, The Journal of experimental medicine.

[39]  V. Perry,et al.  The acute inflammatory response to lipopolysaccharide in cns parenchyma differs from that in other body tissues , 1992, Neuroscience.

[40]  N. Copeland,et al.  Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis , 1992, Nature.

[41]  R. Knobler,et al.  Distribution of the Blood‐Brain Barrier in Heterotopic Brain Transplants and its Relationship to the Lesions of EAE , 1992, Journal of neuropathology and experimental neurology.

[42]  P. Bretscher.  The two-signal model of lymphocyte activation twenty-one years later. , 1992, Immunology today.

[43]  C. Kufta,et al.  Adult human glial cells can present target antigens to HLA-restricted cytotoxic T-cells , 1990, Journal of Neuroimmunology.

[44]  R. Schwartz,et al.  Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. , 1989, Annual review of immunology.

[45]  K. Tanaka,et al.  Rejection of B16 melanoma induced by expression of a transfected major histocompatibility complex class I gene , 1988, Molecular and cellular biology.

[46]  W. Boswell,et al.  Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected]. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  D. Paterson,et al.  Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts. , 1987, Molecular immunology.

[48]  S. Rosenberg,et al.  Adoptive immunotherapy of newly induced murine sarcomas. , 1985, Cancer research.

[49]  I. Hart.  The selection and characterization of an invasive variant of the B16 melanoma. , 1979, The American journal of pathology.

[50]  N. Di Lorenzo,et al.  Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas. Incidence, fate, and relevance to prognosis in 228 operated cases. , 1978, Journal of neurosurgery.

[51]  D. Rall,et al.  Studies on the chemotherapy of experimental brain tumors: development of an experimental model. , 1970, Cancer research.

[52]  A. S. Wiener,et al.  Transplantation , 1963 .